Black patients with metastatic triple-negative breast cancer received immunotherapy less frequently than patients of other racial or ethnic backgrounds, according to results of a retrospective cohort ...
IDEAYA Biosciences, Inc.’s IDYA share price has surged by 10.70%, which has investors questioning if this is right time to sell.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback